- Home
- RIGL vs AXG Comparison
RIGL vs AXG Comparison
Compare RIGL & AXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | AXG |
|---|---|---|
| Founded | 1996 | 2021 |
| Country | United States | Hong Kong |
| Employees | N/A | 33 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 712.4M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | AXG |
|---|---|---|
| Price | $29.44 | $3.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $45.67 | N/A |
| AVG Volume (30 Days) | 261.8K | ★ 412.4K |
| Earning Date | 05-05-2026 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 19.48 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | $28.53 |
| Revenue Next Year | $12.75 | $54.60 |
| P/E Ratio | $1.57 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $16.05 | $2.69 |
| 52 Week High | $52.24 | $4.75 |
Technical Indicators
Market Signals| Indicator | RIGL | AXG |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 37.76 |
| Support Level | $28.08 | $3.26 |
| Resistance Level | $30.59 | $3.90 |
| Average True Range (ATR) | 1.10 | 0.20 |
| MACD | 0.74 | -0.02 |
| Stochastic Oscillator | 77.44 | 0.81 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About AXG Solowin Holdings Class A Ordinary Share
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.